Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts
- PMID: 1993850
Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts
Abstract
Spleen cells of BALB/c mice bearing a syngeneic CSA1M fibrosarcoma were treated with anti-Thy-1.2 antibody plus C, yielding a T cell-depleted, APC-containing fraction. The APC-containing fraction was first tested for its capacity to present exogenous modified-self or another tumor (Meth A) Ag after in vitro pulsing. The results showed comparable Ag-presenting capacities to those obtained by APC-containing fraction from normal spleen cells, indicating that APC function is not affected in tumor-bearing mice. We next examined whether APC from CSA1M-bearing mice bind endogenously generated CSA1M tumor Ag onto its surfaces to stimulate tumor-specific T cells. Five rounds of inoculation of APC-containing fraction from CSA1M-bearing mice without further in vitro pulsing resulted in the induction of potent anti-CSA1M immune resistance. The involvement of anti-CSA1M T cells in the induction of anti-CSA1M immunity was excluded by the fact that the in vivo immunity was excluded by the fact that the in vivo immunity was delivered by Thy-1+ cell-depleted, but not by Thy-1+ cell-enriched fractions of spleen cells from CSA1M-bearing mice. Moreover, the failure of Sephadex G10-passed spleen cells to deliver anti-CSA1M resistance demonstrated the absolute requirement of APC for inducing the in vivo immunity. Finally, this in vivo resistance was found to be tumor specific, because APC fractions from CSA1M-bearing and Meth A-bearing BALB/c mice induced immune resistance selective against the corresponding tumor cell challenge. These results indicate that APC from tumor-bearing hosts can not only exert unaffected APC function against exogenous Ag, but also function to present tumor Ag generated endogenously in the tumor-bearing state and to produce tumor-specific immunity in vivo.
Similar articles
-
Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.J Immunol. 1989 Feb 1;142(3):1053-9. J Immunol. 1989. PMID: 2464022
-
Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen-presenting cells.Princess Takamatsu Symp. 1988;19:265-75. Princess Takamatsu Symp. 1988. PMID: 3269360
-
Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.J Immunol. 1992 Jan 15;148(2):648-55. J Immunol. 1992. PMID: 1345922
-
[Biochemical characterization of tumor rejection antigen (TRA) and genetic control in anti-TRA immune responses].Gan To Kagaku Ryoho. 1989 Mar;16(3 Pt 2):646-52. Gan To Kagaku Ryoho. 1989. PMID: 2468311 Review. Japanese.
-
Differential antigen presentation in tumor immunity.Fed Proc. 1984 Jun;43(9):2460-4. Fed Proc. 1984. PMID: 6327399 Review.
Cited by
-
Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides.Immunology. 1997 Aug;91(4):635-42. doi: 10.1046/j.1365-2567.1997.00287.x. Immunology. 1997. PMID: 9378506 Free PMC article.
-
Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.Immunol Res. 1995;14(4):271-91. doi: 10.1007/BF02935625. Immunol Res. 1995. PMID: 8722044 Review.
-
Transforming growth factor-beta (TGF-beta)-mediated immunosuppression in the tumor-bearing state: enhanced production of TGF-beta and a progressive increase in TGF-beta susceptibility of anti-tumor CD4+ T cell function.Jpn J Cancer Res. 1993 Mar;84(3):315-25. doi: 10.1111/j.1349-7006.1993.tb02873.x. Jpn J Cancer Res. 1993. PMID: 8098027 Free PMC article.
-
Recovery of antitumor CD4+ T cell responsiveness, suppressed in the tumor-bearing state, by release from tumor burden.J Cancer Res Clin Oncol. 1994;120(5):279-85. doi: 10.1007/BF01236384. J Cancer Res Clin Oncol. 1994. PMID: 7907334
-
Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden.Jpn J Cancer Res. 1993 Nov;84(11):1181-9. doi: 10.1111/j.1349-7006.1993.tb02819.x. Jpn J Cancer Res. 1993. PMID: 7903964 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous